clinical trial · NCT03919240
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
The First Affiliated Hospital of Soochow University·phase2·recruiting·n = 196
Acute Lymphoblastic Leukemia With Failed RemissionCAR T-cell therapy
brief summary
Refractory and relapsed (R/R) acute lymphoblastic leukemia (ALL) patients with active disease always have a dismal outcome. Chimeric antigen receptor (CAR) T-cell therapy targeting to Cluster of Differentiation Antigen 19 (CD19) has been proved as a potent approach to attain remission in B-cell R/R patients. Therefore, the investigators conduct atrial to evaluate the the efficacy and safety of locally producing CAR T cells targeting CD19, and to analyze the outcome of enrolled B-cell ALL patients with active disease or persistent residual disease.
started
Dec 1, 2015
primary completion
Aug 30, 2027
completion
Dec 31, 2027
last updated
Apr 21, 2026
official title
CD19-targeting Chimeric Antigen Receptor T-cell Therapy for Patients With Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol